市場調査レポート

商品コード

1206472

アジア太平洋地域の過活動膀胱治療市場の2028年までの予測- 地域別分析- 薬物療法別、疾患タイプ別

Asia Pacific Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type

出版日: 2023年01月23日 | 発行: The Insight Partners

| ページ情報: 英文 160 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 3,000 476,910円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 4,000 635,880円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 5,000 794,850円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=158.97円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

アジア太平洋地域の過活動膀胱治療市場は、2022年の8億7,148万米ドルから2028年には10億8,225万米ドルに成長すると予測され、2022年から2028年までのCAGRは3.7%と推定されています。

薬剤の強固なパイプラインと新規治療薬の相次ぐ発売がアジア太平洋地域の過活動膀胱治療を強化する

2020年12月、β3アゴニストで成人の過活動膀胱の新規治療薬であるGemtesaの新薬申請が承認されました。Urovant Sciences社が提供するGemtesa（ビベグロン）は、膀胱留置筋を弛緩させ、膀胱がより多くの尿を保持できるようにする効果があり、この筋肉の弛緩により過活動膀胱の症状が軽減します。1日1回の服用で、用量の漸増が不要な過活動膀胱治療は初めてです。多くの大学や学術機関が、過活動膀胱を治療する新規分子の研究開発を精力的に行っています。例えば、韓国ソウルの延世大学医学部・セブランス病院では、新規ムスカリンM3受容体拮抗薬「DA8010」の評価を進めています。2021年9月、同大学は、第2相試験において、M3拮抗薬DA8010が過活動膀胱治療の有効性と安全性を実証したことを発表しました。過活動膀胱治療の強固なパイプラインと、新規薬剤や治療薬の相次ぐ発売は、今後数年間、アジア太平洋地域の過活動膀胱治療市場の成長を促進すると期待されます。

アジア太平洋地域の過活動膀胱治療市場の概要

アジア太平洋地域の過活動膀胱治療市場は、中国、日本、インド、韓国、オーストラリア、その他アジア太平洋地域に区分されます。市場成長の背景には、高齢者人口の増加、尿失禁症例の増加、製品発売の増加などがあります。過活動膀胱は、腹部外傷、尿感染症、尿失禁、神経損傷などが原因で引き起こされます。National Centre for Biotechnology（NCBI）によると、2019年、中国では40歳以上の5人に1人が過活動膀胱症候群の症状を確認されました。中国医学雑誌によると、2019年の18歳以上の過活動膀胱の症例率は5.9%でした。世界保健機関（WHO）によると、中国の60歳以上の高齢者は、2021年の10％から2041年には28％に増加すると予想されています。さらに、「World Population Aging 2019」によると、香港では2019年に60歳以上の人が総人口の17.5％を占めています。老年人口の増加に伴い、過活動膀胱や尿路感染症を患う患者数は今後数年で増加すると予想されます。これらすべての要因が、アジア太平洋地域の過活動膀胱治療市場の成長に寄与しています。

アジア太平洋地域の過活動膀胱治療市場の収益と2028年までの予測

アジア太平洋地域の過活動膀胱治療市場のセグメンテーション

アジア太平洋地域の過活動膀胱治療市場は、薬物療法、疾患タイプ、国別に区分されます。

薬物療法に基づくと、アジア太平洋地域の過活動膀胱治療市場は、抗コリン薬、ミラベグロン、ボトックス、神経刺激、膀胱内注入に細分化されます。ミラベグロンセグメントは、2022年にアジア太平洋地域の過活動膀胱治療市場で最大のシェアを登録しました。

疾患タイプに基づき、アジア太平洋地域の過活動膀胱治療市場は特発性過活動膀胱と神経原性膀胱に二分されます。2022年の市場では、特発性過活動膀胱分野がより大きなシェアを占めています。

国別に見ると、アジア太平洋地域の過活動膀胱治療市場は、中国、日本、インド、韓国、オーストラリア、韓国、その他アジア太平洋地域に区分されます。2022年は中国が市場を独占。

AbbVie Inc、Alembic Pharmaceuticals Limited、Astellas Pharma Inc、Endo Pharmaceuticals Inc、Hisamitsu Pharmaceutical Co., Inc.、Medtronic Plc、Pfizer Inc、Teva Pharmaceutical Industries Ltdは、アジア太平洋地域の過活動膀胱治療市場で事業を展開している主要企業です。

List Of Tables

Table 1. China Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 2. China Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 3. China Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 4. China Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 5. Japan Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 7. Japan Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 8. Japan Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 9. India Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 10. India Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 11. India Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 12. India Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 13. South Korea Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 14. South Korea Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 15. South Korea Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 16. South Korea Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 17. Australia Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 18. Australia Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 19. Australia Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 20. Australia Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of APAC Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of APAC Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of APAC Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of APAC Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 25. Organic Developments Done by Companies
Table 26. Glossary of Terms

List Of Figures

Figure 1. APAC Overactive Bladder Treatment Market Segmentation
Figure 2. APAC Overactive Bladder Treatment Market Segmentation, By Country
Figure 3. APAC Overactive Bladder Treatment Market Overview
Figure 4. Mirabegron Segment Held Largest Share by Pharmacotherapy in APAC Overactive Bladder Treatment market
Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. APAC: PEST Analysis
Figure 8. APAC Overactive Bladder Treatment Market: Impact Analysis of Driver and Restraints
Figure 9. APAC Overactive Bladder Treatment Market - Revenue Forecast and Analysis - 2020- 2028
Figure 10. APAC Overactive Bladder Treatment Market, by Pharmacotherapy 2021 & 2028 (%)
Figure 11. Mirabegron: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Botox: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Neurostimulation: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Transcutaneous Sacral Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 15. Transcutaneous Tibial Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ MN)
Figure 16. Percutaneous Posterior Tibial Nerve: APAC Overactive Bladder Stimulation Market Revenue and Forecasts To 2028 (US$ MN)
Figure 17. Others: APAC Overactive Bladder Market Revenue and Forecasts To 2028 (US$ MN)
Figure 18. Anticholinergics: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Solifenacin: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Oxybutynin: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Fesoterodine: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Darifenacin: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Tolterodine: APAC Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Trospium: APAC Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Other Anticholinergics: APAC Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Intravesical Instillation: APAC Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. APAC Overactive Bladder Treatment Market, by Disease Type 2021 & 2028 (%)
Figure 28. Idiopathic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Neurogenic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 30. APAC: Overactive Bladder Treatment Market, by Key Country - Revenue (2021) (US$ Million)
Figure 31. China: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Japan: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. India: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. South Korea: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. Australia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Rest of APAC: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)

Product Code: BMIRE00027905

The Asia Pacific overactive bladder treatment market is expected to grow from US$ 871.48 million in 2022 to US$ 1,082.25 million by 2028; it is estimated to grow at a CAGR of 3.7% from 2022 to 2028.

Robust Pipeline of Drugs and Successive Launch of Novel Therapies to Bolster Asia Pacific Overactive Bladder Treatment

In December 2020, a new drug application was approved for Gemtesa, a beta 3-agonist and a novel treatment for overactive bladder in adults. Gemtesa (vibegron), provided by Urovant Sciences, helps in relaxing the detrusor bladder muscle, which enables the bladder to hold more urine; the relaxation of this muscle reduces overactive bladder symptoms. It is a once-daily pill and the first overactive bladder medication that does not require dose titration. Many universities and academic institutions are conducting robust research and development activities on novel molecules to treat OAB. For instance, the Yonsei University College of Medicine and Severance Hospital, Seoul, South Korea, is evaluating DA8010, a novel muscarinic M3 receptor antagonist. In September 2021, the university published that in the phase 2 trial, the M3 antagonist DA8010 was demonstrated for the efficacy and safety of overactive bladder treatment. The robust pipeline of drugs for overactive bladder treatment and the successive launch of novel drugs and therapies are expected to drive the growth of the Asia Pacific overactive bladder treatment market in the coming years.

Asia Pacific Overactive Bladder Treatment Market Overview

The Asia Pacific overactive bladder treatment market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. The market growth is attributed to the rising geriatric population, increasing urinary incontinence cases, and a growing number of product launches. Overactive bladder is caused due to abdominal trauma, urinary infection, urinary incontinence, and nerve damage. According to National Centre for Biotechnology (NCBI), in 2019, 1 in 5 individuals above 40 years was identified with symptoms of overactive bladder syndrome in China. The Chinese Medical Journal stated that the rate of overactive bladder cases was 5.9% among people over 18 years in 2019. According to World Health Organization, people aged 60 years in China are expected to grow from 10% in 2021 to 28% by 2041. Further, as per the World Population Aging 2019, in Hong Kong, people aged 60 years and older accounted for 17.5% of the total population in 2019. With the growing geriatric population, the number of patients having an overactive bladder and urinary tract infection is expected to increase in the coming years. All these factors are contributing to the Asia Pacific overactive bladder treatment market growth.

Asia Pacific Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Overactive Bladder Treatment Market Segmentation

The Asia Pacific overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the Asia Pacific overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the Asia Pacific overactive bladder treatment market in 2022.

Based on disease type, the Asia Pacific overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.

Based on country, the Asia Pacific overactive bladder treatment market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.

AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Asia Pacific overactive bladder treatment market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific overactive bladder treatment market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific overactive bladder treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the overactive bladder treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 APAC Overactive Bladder Treatment Market- By Pharmacotherapy
- 1.3.2 APAC Overactive Bladder Treatment Market- By Disease Type
- 1.3.3 APAC Overactive Bladder Treatment Market - By Country

2. APAC Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. APAC Overactive Bladder Treatment Market - Market Landscape

4.1 Overview
4.2 APAC PEST Analysis
4.3 Expert Opinion

5. APAC Overactive Bladder Treatment Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Prevalence of Urinary Incontinence
- 5.1.2 Growing Incidence of Urinary Tract Infections
5.2 Key Market Restraints
- 5.2.1 Recalls of Therapeutic Drugs
5.3 Key Market Opportunities
- 5.3.1 Increasing Number of Mergers and Acquisitions
5.4 Future Trends
- 5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
5.5 Impact analysis

6. Overactive Bladder Treatment Market - APAC Analysis

6.1 APAC Overactive Bladder Treatment Market Revenue Forecast and Analysis

7. APAC Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

7.1 Overview
7.2 APAC Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
7.3 Mirabegron
- 7.3.1 Overview
- 7.3.2 Mirabegron: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.4 Botox
- 7.4.1 Overview
- 7.4.2 Botox: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.5 Neurostimulation
- 7.5.1 Overview
- 7.5.2 Neurostimulation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.3 Transcutaneous Sacral Nerve Stimulation
  - 7.5.3.1 Overview
  - 7.5.3.2 Transcutaneous Sacral Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.4 Transcutaneous Tibial Nerve Stimulation
  - 7.5.4.1 Overview
  - 7.5.4.2 Transcutaneous Tibial Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
  - 7.5.5.1 Overview
  - 7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.6 Others
  - 7.5.6.1 Overview
  - 7.5.6.2 Others: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Anticholinergics
- 7.6.1 Overview
- 7.6.2 Anticholinergics: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.3 Solifenacin
  - 7.6.3.1 Overview
  - 7.6.3.2 Solifenacin: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.4 Oxybutynin
  - 7.6.4.1 Overview
  - 7.6.4.2 Oxybutynin: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.5 Fesoterodine
  - 7.6.5.1 Overview
  - 7.6.5.2 Fesoterodine: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.6 Darifenacin
  - 7.6.6.1 Overview
  - 7.6.6.2 Darifenacin: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.7 Tolterodine
  - 7.6.7.1 Overview
  - 7.6.7.2 Tolterodine: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.8 Trospium
  - 7.6.8.1 Overview
  - 7.6.8.2 Trospium: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.9 Other Anticholinergics
  - 7.6.9.1 Overview
  - 7.6.9.2 Other Anticholinergics: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.7 Intravesical Instillation
- 7.7.1 Overview
- 7.7.2 Intravesical Instillation: APAC Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

8. APAC Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

8.1 Overview
8.2 APAC Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
8.3 Idiopathic Overactive Bladder
- 8.3.1 Overview
- 8.3.2 Idiopathic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Neurogenic Overactive Bladder
- 8.4.1 Overview
- 8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

9.1 Overview
- 9.1.1 APAC: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
  - 9.1.1.1 China: overactive bladder treatment Market - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.1.1 China: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.1.2 China: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.1.2.1 China: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.1.2.2 China Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.1.3 China: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.2 Japan: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.2.1 Japan: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.2.2 Japan: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.2.2.1 Japan: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.2.2.2 Japan Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.2.3 Japan: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.3 India: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.3.1 India: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.3.2 India: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.3.2.1 India: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.3.2.2 India Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.3.3 India: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.4 South Korea: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.4.1 South Korea: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.4.2 South Korea: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.4.2.1 South Korea: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.4.2.2 South Korea Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.4.3 South Korea: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.5 Australia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.5.1 Australia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.5.2 Australia: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.5.2.1 Australia: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.5.2.2 Australia Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.5.3 Australia: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.6 Rest of APAC: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.6.1 Rest of APAC: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.6.2 Rest of APAC: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.6.2.1 Rest of APAC: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.6.2.2 Rest of APAC Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.6.3 Rest of APAC: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)

10. Overactive Bladder Treatment Market- Industry Landscape

10.1 Overview
10.2 Organic Developments
- 10.2.1 Overview

11. Company Profiles

11.1 Alembic Pharmaceuticals Limited
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Astellas Pharma Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 AbbVie Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Teva Pharmaceutical Industries Ltd
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Endo Pharmaceuticals Inc.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co. Inc.
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Medtronic Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Pfizer Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

アジア太平洋地域の過活動膀胱治療市場の2028年までの予測- 地域別分析- 薬物療法別、疾患タイプ別

Asia Pacific Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type

目次

第1章イントロダクション

第2章アジア太平洋地域の過活動膀胱治療市場- 主要な要点

第3章調査手法

第4章アジア太平洋地域の過活動膀胱治療市場- 市場情勢

第5章アジア太平洋地域の過活動膀胱治療市場- 主要市場力学

第6章過活動膀胱治療市場- アジア太平洋地域分析

第7章アジア太平洋地域の過活動膀胱治療市場分析と2028年までの予測- 薬物療法別

第8章アジア太平洋地域の過活動膀胱治療市場の分析と2028年までの予測- 疾患タイプ別

第9章過活動膀胱治療市場の収益と2028年までの予測- 国別分析

第10章過活動膀胱治療市場- 業界情勢

第11章企業プロファイル

第12章付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. APAC Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

4. APAC Overactive Bladder Treatment Market - Market Landscape

5. APAC Overactive Bladder Treatment Market - Key Market Dynamics

6. Overactive Bladder Treatment Market - APAC Analysis

7. APAC Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

8. APAC Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

10. Overactive Bladder Treatment Market- Industry Landscape

11. Company Profiles

12. Appendix

アジア太平洋地域の過活動膀胱治療市場の2028年までの予測- 地域別分析- 薬物療法別、疾患タイプ別

Asia Pacific Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type

目次

第1章 イントロダクション

第2章 アジア太平洋地域の過活動膀胱治療市場- 主要な要点

第3章 調査手法

第4章 アジア太平洋地域の過活動膀胱治療市場- 市場情勢

第5章 アジア太平洋地域の過活動膀胱治療市場- 主要市場力学

第6章 過活動膀胱治療市場- アジア太平洋地域分析

第7章 アジア太平洋地域の過活動膀胱治療市場分析と2028年までの予測- 薬物療法別

第8章 アジア太平洋地域の過活動膀胱治療市場の分析と2028年までの予測- 疾患タイプ別

第9章 過活動膀胱治療市場の収益と2028年までの予測- 国別分析

第10章 過活動膀胱治療市場- 業界情勢

第11章 企業プロファイル

第12章 付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. APAC Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

4. APAC Overactive Bladder Treatment Market - Market Landscape

5. APAC Overactive Bladder Treatment Market - Key Market Dynamics

6. Overactive Bladder Treatment Market - APAC Analysis

7. APAC Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

8. APAC Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

10. Overactive Bladder Treatment Market- Industry Landscape

11. Company Profiles

12. Appendix

第1章イントロダクション

第2章アジア太平洋地域の過活動膀胱治療市場- 主要な要点

第3章調査手法

第4章アジア太平洋地域の過活動膀胱治療市場- 市場情勢

第5章アジア太平洋地域の過活動膀胱治療市場- 主要市場力学

第6章過活動膀胱治療市場- アジア太平洋地域分析

第7章アジア太平洋地域の過活動膀胱治療市場分析と2028年までの予測- 薬物療法別

第8章アジア太平洋地域の過活動膀胱治療市場の分析と2028年までの予測- 疾患タイプ別

第9章過活動膀胱治療市場の収益と2028年までの予測- 国別分析

第10章過活動膀胱治療市場- 業界情勢

第11章企業プロファイル

第12章付録